Single and multiple dose evaluation of a novel MetAP2 inhibitor: results of a randomised, double-blind, placebo-controlled clinical trial

被引：0
|
作者：
Malloy, J. [1 ]
Zhuang, D. [1 ]
Kim, T. [1 ]
Kim, D. [1 ]
Taylor, K. [1 ]
机构：
[1] Zafgen Inc, Boston, MA USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
850
引用
收藏
页码：S394 / S394
页数：1
相关论文
共 50 条
  • [1] Single and Multiple Dose Evaluation of a Novel MetAP2 Inhibitor: Results of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Malloy, Jaret
    Zhuang, Dongliang
    Kim, Terri
    Kim, Dennis
    Taylor, Kristin
    DIABETES, 2017, 66 : LB38 - LB38
  • [2] Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial
    Malloy, Jaret
    Zhuang, Dongliang
    Kim, Terri
    Inskeep, Phil
    Kim, Dennis
    Taylor, Kristin
    DIABETES OBESITY & METABOLISM, 2018, 20 (08): : 1878 - 1884
  • [3] Final Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the MetAP2 Inhibitor ZGN-1061 in Patients with Type 2 Diabetes
    Kim, Terri
    Zhuang, Dongliang
    Haugen, Tonya L.
    Kim, Dennis D.
    Taylor, Kristin
    DIABETES, 2019, 68
  • [4] Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial
    McCandless, Shawn E.
    Yanovski, Jack A.
    Miller, Jennifer
    Fu, Cary
    Bird, Lynne M.
    Salehi, Parisa
    Chan, Christine L.
    Stafford, Diane
    Abuzzahab, M. Jennifer
    Viskochil, David
    Barlow, Sarah E.
    Angulo, Moris
    Myers, Susan E.
    Whitman, Barbara Y.
    Styne, Dennis
    Roof, Elizabeth
    Dykens, Elisabeth M.
    Scheimann, Ann O.
    Malloy, Jaret
    Zhuang, Dongliang
    Taylor, Kristin
    Hughes, Thomas E.
    Kim, Dennis D.
    Butler, Merlin G.
    DIABETES OBESITY & METABOLISM, 2017, 19 (12): : 1751 - 1761
  • [5] A first-in-human randomised double-blind placebo-controlled clinical trial of a novel narrow spectrum kinase inhibitor
    Rowley, A.
    Duggal, A.
    Taylor, M.
    Foster, M.
    Solanke, Y.
    Sirohi, S.
    Walshe, C.
    Webber, S.
    Irving, P.
    Travis, S.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S385 - S385
  • [6] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
    Kappos, Ludwig
    Hartung, Hans-Peter
    Freedman, Mark S.
    Boyko, Alexey
    Radue, Ernst Wilhelm
    Mikol, Daniel D.
    Lamarine, Marc
    Hyvert, Yann
    Freudensprung, Ulrich
    Plitz, Thomas
    van Beek, Johan
    LANCET NEUROLOGY, 2014, 13 (04): : 353 - 363
  • [7] Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
    Hartung, HP
    Gonsette, R
    König, N
    Kwiecinski, H
    Guseo, A
    Morrissey, SP
    Krapf, H
    Zwingers, T
    LANCET, 2002, 360 (9350): : 2018 - 2025
  • [8] Evaluation of antioxidant treatment in presbyacusis: prospective, placebo-controlled, double-blind, randomised trial
    Polanski, J. F.
    Cruz, O. L.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2013, 127 (02): : 134 - 141
  • [9] Low-dose mifepristone in treatment of uterine leiomyoma: A randomised double-blind placebo-controlled clinical trial
    Bagaria, Madhu
    Suneja, Amita
    Vaid, Neelam B.
    Guleria, Kiran
    Mishra, Kiran
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2009, 49 (01): : 77 - 83
  • [10] Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial
    Miller, David H.
    Weber, Thomas
    Grove, Richard
    Wardell, Claire
    Horrigan, Joseph
    Graff, Ole
    Atkinson, Gillian
    Dua, Pinky
    Yousry, Tarek
    MacManus, David
    Montalban, Xavier
    LANCET NEUROLOGY, 2012, 11 (02): : 131 - 139
12345